文献速递炎症性肠病

综述:炎症性肠病中的真菌改变

Review article: fungal alterations in inflammatory bowel diseases.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-24

本综述通过检索Ovid和Pubmed相关动物与人类研究,总结肠道真菌在炎症性肠病(IBD)中的作用及其与细菌的跨界相互作用。克罗恩病患者粪便和黏膜中真菌总负荷增加(尤其念珠菌和马拉色菌),溃疡性结肠炎患者粪便真菌多样性降低;CARD9多态性促进马拉色菌定植并加重肠道炎症,饮食和抗真菌/益生菌干预可能影响病程。

要点

  • 克罗恩病患者真菌总负荷增加,以念珠菌和马拉色菌为主。
  • 溃疡性结肠炎患者粪便真菌多样性降低。
  • 调节真菌微生物群可能成为IBD治疗途径。

核心结论

  • 克罗恩病和溃疡性结肠炎患者肠道真菌发生改变,调节真菌微生物群可考虑作为IBD的治疗方法。

研究设计与样本

  • 在Ovid和Pubmed进行文献检索,选择报告真菌与IBD的相关动物和人类研究进行综述。

主要发现

  • 克罗恩病患者粪便和黏膜中真菌总负荷增加,尤其是念珠菌和马拉色菌。
  • 溃疡性结肠炎患者粪便中真菌多样性较低。
  • 克罗恩病患者CARD9多态性有利于马拉色菌定植,从而加重肠道炎症。
  • 高碳水化合物饮食增加念珠菌总丰度,而富含蛋白质饮食则相反。
  • 补充纤维孢酵母、布拉氏酵母菌和酿酒酵母CNCM I-3856菌株的初步研究显示对IBD有治疗效应。

关键数值与推荐

  • 抗真菌治疗主要用于治疗IBD中的白念珠菌或荚膜组织胞浆菌感染。

临床怎么用

  • 临床可关注IBD患者肠道真菌改变,未来或可通过调节真菌微生物群进行治疗。

局限性

  • 未来研究应聚焦于理解真菌微生物群与肠道其他微生物组分如何相互作用并与IBD发病和发展相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging data suggest that alterations in gut fungi may be associated with the pathogenesis of inflammatory bowel disease (IBD). In healthy individuals, gut commensal fungi act synergistically with other members of the microbiota to maintain homeostasis but their role in IBD is less clear. AIM: To review the role of gut fungi and their trans-kingdom interactions with bacteria in IBD METHODS: A literature search was conducted on Ovid and Pubmed to select relevant animal and human studies that have reported fungi and IBD. RESULTS: There is an increased total fungal load particularly of Candida and Malassezia species in the faeces and mucosa of Crohn's disease patients, and a lower fungal diversity in the faeces of ulcerative colitis patients. Caspase recruitment domain-containing protein (CARD)-9 polymorphism in Crohn's disease patients favours Malassezia colonisation that worsens gut inflammation. Diet high in carbohydrates increased the total abundance of Candida species, whereas protein-rich diet had the opposite effect. Anti-fungal therapies are mostly used to treat Candida albicans or Histoplasma capsulatum infections in IBD, whereas pilot studies of supplementing fungal probiotics Saccharomycopsis fibuligera, Saccharomyces boulardii and Saccharomyces cerevisiae CNCM I-3856 strain showed therapeutic effects in IBD. CONCLUSIONS: Gut fungi are altered in patients with Crohn's disease and ulcerative colitis. Modulation of the fungal microbiota can be considered as a therapeutic approach for IBD. Future research should focus on understanding how the fungal microbiota interacts with other components of the gut microbiota in association with the pathogenesis and development of IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lam S, Zuo T, Ho M, et al. Review article: fungal alterations in inflammatory bowel diseases. Aliment Pharmacol Ther. 2019. PMID: 31648369. doi:10.1111/apt.15523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。